Antisense drug discovery and development

Future Medicinal Chemistry

Volumn 3, Issue 3, 2011, Pages 339-365

  Yamamoto, Tsuyoshi ^a   Nakatani, Moeka ^a   Narukawa, Keisuke ^a   Obika, Satoshi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 35156; ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; APRINOCARSEN; ATL 1102; AZINPHOS ETHYL; BORANE DERIVATIVE; CENERSEN; CGP 69846A; DNA; FOMIVIRSEN; G 4460; GENE EXPRESSION MODULATOR 231; GSK 2402968; GTI 2040; ICO 007; ISIS 104838; ISIS 13715; ISIS 23722; ISIS 2503; MESSENGER RNA; METHYLPHOSPHONIC ACID; MIPOMERSEN; NUCLEASE; NUCLEOSIDE ANALOG; OBLIMERSEN; OLIGOMER; PHOSPHORIC ACID; PHOSPHOROTHIOIC ACID; RNA; TRABEDERSEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEGLIN;

ANTISENSE THERAPY; CHEMICAL MODIFICATION; DRUG DEVELOPMENT; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELTING POINT; MULTIGENE FAMILY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; STEREOISOMERISM;

ANTIVIRAL AGENTS; BRIDGED COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; DNA, ANTISENSE; DRUG DISCOVERY; DYSTROPHIN; HUMANS; MORPHOLINES; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RNA; THIONUCLEOTIDES;

EID: 79953254828     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.11.2     Document Type: Review

References (215)

1. Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97, 225-236 (2008).
2. Rayburn ER, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible? Drug Discov. Today 13, 513-521 (2008).
3. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75, 280-284 (1978). (Pubitemid 8290783)
4. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl Acad. Sci. USA 75, 285-288 (1978). (Pubitemid 8290784)
5. Miller PS, McParland KB, Jayaraman K, Ts'o PO. Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20, 1874-1880 (1981).
6. Blake KR, Murakami A, Spitz SA et al. Hybridization arrest of globin synthesis in rabbit reticulocyte lysates and cells by oligodeoxyribonucleoside methylphosphonates. Biochemistry 24, 6139-6145 (1985). (Pubitemid 16197366)
7. Matsukura M, Shinozuka K, Zon G et al. Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl Acad. Sci. USA 84, 7706-7710 (1987).
8. Lima WF, Crooke ST. Binding affinity and specificity of Escherichia coli RNase H1: Impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36, 390-398 (1997). (Pubitemid 27043475)
9. Crooke ST, Lemonidis KM, Neilson L et al. Kinetic characteristics of Escherichia coli RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312, 599-608 (1995). (Pubitemid 26002231)
10. Minasov G, Teplova M, Nielsen P, Wengel J, Egli M. Structural basis of cleavage by RNase H of hybrids of arabinonucleic acids and RNA. Biochemistry 39, 3525-3532 (2000). (Pubitemid 30183833)
11. Vester B, Boel AM, Lobedanz S et al. Chemically modified oligonucleotides with efficient RNase H response. Bioorg. Med. Chem. Lett. 18, 2296-2300 (2008). (Pubitemid 351442904)
12. Eisen JS, Smith JC. Controlling morpholino experiments: Don't stop making antisense. Development 135, 1735-1743 (2008).
13. Sugita H, Takeda S. Progress in muscular dystrophy research with special emphasis on gene therapy. P. Jpn Acad. B-Phys. 86, 748-756 (2010).
14. Crooke ST. Progress in antisense technology. Annu. Rev. Med. 55, 61-95 (2004). (Pubitemid 38316716)
15. Crooke ST. Antisense Drug Technologies: Principles, Strategies, and Applications (2nd Edition). CRC Press (2007). Comprehensive review of antisense chemistry and pharmacology.
16. Uhlmann E, Peyman A. Antisense oligonucleotides - a new therapeutic principle. Chem. Rev. 90, 543-584 (1990).
17. Freier SM, Altmann KH. The ups and downs of nucleic acid duplex stability: Structure- stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429-4443 (1997). (Pubitemid 27500751)
18. Micklefield J. Backbone modification of nucleic acids: Synthesis, structure and therapeutic applications. Curr. Med. Chem. 8, 1157-1179 (2001). (Pubitemid 32655075)
19. Wilson C, Keefe AD. Building oligonucleotide therapeutics using nonnatural chemistries. Curr. Opin. Chem. Biol. 10, 607-614 (2006). (Pubitemid 44821893)
20. Prakash TP, Siwkowski A, Allerson CR et al. Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-Caminomethylene bridged nucleoside analogues show improved potency in animal models. J. Med. Chem. 53, 1636-1650 (2010). Describes the medicinal chemistry of 2',4'-bridged nucleic acid (BNA).
21. Seth PP, Allerson CR, Berdeja A et al. An exocyclic methylene group acts as a bioisostere of the 2'-oxygen atom in LNA. J. Am. Chem. Soc. 132, 14942-14950 (2010). Describes the medicinal chemistry of 2',4'-BNA.
22. Oivanen M, Ora M, Almer H, Stromberg R, Lonnberg H. Hydrolytic reactions of the diastereomeric phosphoromonothioate analogs of uridylyl(3',5') uridine - kinetics and mechanisms for desulfurization, phosphoester hydrolysis, and transesterification to the 2',5'-isomers. J. Org. Chem. 60, 5620-5627 (1995).
23. Summers JS, Shaw BR. Boranophosphates as mimics of natural phosphodiesters in DNA. Curr. Med. Chem. 8, 1147-1155 (2001). (Pubitemid 32655074)
24. Stec WJ, Zon G, Egan W, Stec B. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106, 6077-6079 (1984). (Pubitemid 14012080)
25. Iyer RP, Egan W, Regan JB, Beaucage SL. 3H-1,2-benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112, 1253-1254 (1990). (Pubitemid 20127085)
26. Yu D, Kandimalla ER, Roskey A et al. Stereo-enriched phosphorothioate oligodeoxgnucleotides: Synthesis, biophysical and biological properties. Bioorgan. Med. Chem. 8, 275-284 (2000). (Pubitemid 30125677)
27. Stec WJ, Grajkowski A, Kobylanska A et al. Diastereomers of nucleoside 3'-O-(2-thio- 1,3,2-oxathia(selena)phospholanes) - building-blocks for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)S. J. Am. Chem. Soc. 117, 12019-12029 (1995). (Pubitemid 26022768)
28. Oka N, Wada T, Saigo K. Diastereocontrolled synthesis of dinucleoside phosphorothioates using a novel class of activators, dialkyl (cyanomethyl)ammonium tetrafluoroborates. J. Am. Chem. Soc. 124, 4962-4963 (2002). (Pubitemid 34495881)
29. Oka N, Yamamoto M, Sato T, Wada T. Solid-phase synthesis of stereoregular oligodeoxyribonucleoside phosphorothioates using bicyclic oxazaphospholidine derivatives as monomer units. J. Am. Chem. Soc. 130, 16031-16037 (2008).
30. Sood A, Shaw BR, Spielvogel BF. Boroncontaining nucleic-acids. 2. Synthesis of oligodeoxynucleoside boranophosphates. J. Am. Chem. Soc. 112, 9000-9001 (1990).
31. Li P, Sergueeva ZA, Dobrikov M, Shaw BR. Nucleoside and oligonucleoside boranophosphates: Chemistry and properties. Chem. Rev. 107, 4746-4796 (2007). (Pubitemid 350237040)
32. Summers JS, Roe D, Boyle PD, Colvin M, Shaw BR. Structural studies of a boranemodified phosphate diester linkage: Ab initio calculations on the dimethylboranophosphate anion and the single-crystal x-ray structure of its diisopropylammonium salt. Inorg. Chem. 37, 4158-4159 (1998). (Pubitemid 128483115)
33. Li H, Porter K, Huang F, Shaw BR. Boron-containing oligodeoxyribonucleotide 14mer duplexes: Enzymatic synthesis and melting studies. Nucleic Acids Res. 23, 4495-4501 (1995).
34. Zhang JC, Terhorst T, Matteucci MD. Synthesis and hybridization study of a boranophosphate-linked oligothymidine deoxynucleotide. Tetrahedron Lett. 38, 4957-4960 (1997). (Pubitemid 27345026)
35. Sergueev DS, Shaw BR. H-phosphonate approach for solid-phase synthesis of oligodeoxyribonucleoside boranophosphates and their characterization. J. Am. Chem. Soc. 120, 9417-9427 (1998). (Pubitemid 28452630)
36. Higson AP, Sierzchala A, Brummel H, Zhao ZY, Caruthers MH. Synthesis of an oligothymidylate containing boranophosphate linkages. Tetrahedron Lett. 39, 3899-3902 (1998). (Pubitemid 28228609)
37. Wada T, Shimizu M, Oka N, Saigo K. A new boranophosphorylation reaction for the synthesis of deoxyribonucleoside boranophosphates. Tetrahedron Lett. 43, 4137-4140 (2002). (Pubitemid 34603170)
38. Shimizu M, Wada T, Oka N, Saigo K. A novel method for the synthesis of dinucleoside boranophosphates by a boranophosphotriester method. J. Org. Chem. 69, 5261-5268 (2004). (Pubitemid 39014355)
39. Nielsen J, Brill WKD, Caruthers MH. Synthesis and characterization of dinucleoside phosphorodithioates. Tetrahedron Lett. 29, 2911-2914 (1988).
40. Brill WKD, Nielsen J, Caruthers MH. Synthesis of deoxydinucleoside phosphorodithioates. J. Am. Chem. Soc. 113, 3972-3980 (1991).
41. Bjergarde K, Dahl O. Solid-phase synthesis of oligodeoxyribonucleoside phosphorodithioates from thiophosphoramidites. Nucleic Acids Res. 19, 5843-5850 (1991). (Pubitemid 21912993)
42. Piotto ME, Granger JN, Cho Y, Farschtschi N, Gorenstein DG. Synthesis, NMR and structure of oligonucleotide phosphorodithioates. Tetrahedron 47, 2449-2461 (1991).
43. Marshall WS, Caruthers MH. Phosphorodithioate DNA as a potential therapeutic drug. Science 259, 1564-1569 (1993).
44. Cummins L, Graff D, Beaton G, Marshall WS, Caruthers MH. Biochemical and physicochemical properties of phosphorodithioate DNA. Biochemistry 35, 8734-8741 (1996). (Pubitemid 26240209)
45. Kamaike K, Hirose K, Kayama Y, Kawashima E. Synthesis of oligonucleoside phosphorodithioates by the H-phosphonothioate method. Tetrahedron Lett. 45, 5803-5806 (2004). (Pubitemid 38968554)
46. Kamaike K, Hirose K, Kayama Y, Kawashima E. Synthesis of oligonucleoside phosphorodithioates on a solid support by the H-phosphonothioate method. Tetrahedron 62, 11814-11820 (2006). (Pubitemid 44691861)
47. Saykally RJ, Blake GA. Molecularinteractions and hydrogen-bond tunneling dynamics - some new perspectives. Science 259, 1570-1575 (1993).
48. Cote G, Bauer D. Hydrolysis of the O,O-dialkyl phosphorodithioic acids used as extractants in liquid-liquid systems. Anal. Chem. 56, 2153-2157 (1984). (Pubitemid 14643009)
49. Gryaznov SM, Lloyd DH, Chen JK et al. Oligonucleotide N3'→P5' phosphoramidates. Proc. Natl Acad. Sci. USA 92, 5798-5802 (1995).
50. Tereshko V, Gryaznov S, Egli M. Consequences of replacing the DNA 3'-oxygen by an amino group: Highresolution crystal structure of a fully modified N3'→P5' phosphoramidate DNA dodecamer duplex. J. Am. Chem. Soc. 120, 269-283 (1998). (Pubitemid 28062509)
51. Gryaznov S, Chen JK. Oligodeoxyribonucleotide N3'→5' phosphoramidates - synthesis and hybridization properties. J. Am. Chem. Soc. 116, 3143-3144 (1994).
52. Gryaznov SM. Oligonucleotide N3'→P5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents. Chem. Biodivers. 7, 477-493 (2010).
53. Nelson JS, Fearon KL, Nguyen MQ et al. N3'→P5' oligodeoxyribonucleotide phosphoramidates: A new method of synthesis based on a phosphoramidite amine-exchange reaction. J. Org. Chem. 62, 7278-7287 (1997). (Pubitemid 127494366)
54. Fearon KL, Hirschbein BL, Nelson JS et al. An improved synthesis of oligodeoxynucleotide N3'→P5' phosphoramidates and their chimera using hindered phosphoramidite monomers and a novel handle for reverse phase purification. Nucleic Acids Res. 26, 3813-3824 (1998). (Pubitemid 28367991)
55. Chen JK, Schultz RG, Lloyd DH, Gryaznov SM. Synthesis of oligodeoxyribonucleotide N3'→P5' phosphoramidates. Nucleic Acids Res. 23, 2661-2668 (1995).
56. Skorski T, Perrotti D, Nieborowska- Skorska M, Gryaznov S, Calabretta B. Antileukemia effect of c-myc N3'→P5' phosphoramidate antisense oligonucleotides in vivo. Proc. Natl Acad. Sci. USA 94, 3966-3971 (1997).
57. Kolarovic A, Schweizer E, Greene E et al. Interplay of structure, hydration and thermal stability in formacetal modified oligonucleotides: RNA may tolerate nonionic modifications better than DNA. J. Am. Chem. Soc. 131, 14932-14937 (2009).
58. Matteucci M. Deoxyoligonucleotide analogs based on formacetal linkages. Tetrahedron Lett. 31, 2385-2388 (1990). (Pubitemid 20146886)
59. Dempcy RO, Almarsson O, Bruice TC. Design and synthesis of deoxynucleic guanidine: A polycation analogue of DNA. Proc. Natl Acad. Sci. USA 91, 7864-7868 (1994). (Pubitemid 24253845)
60. Dempcy RO, Browne KA, Bruice TC. Synthesis of the polycation thymidyl dng, its fidelity in binding polyanionic DNA/RNA, and the stability and nature of the hybrid complexes. J. Am. Chem. Soc. 117, 6140-6141 (1995).
61. Dempcy RO, Luo J, Bruice TC. Design and synthesis of ribonucleic guanidine: A polycationic analog of RNA. Proc. Natl Acad. Sci. USA 93, 4326-4330 (1996). (Pubitemid 26144285)
62. Park M, Bruice TC. Binding studies of cationic uridyl ribonucleic guanidine (RNG) to DNA. Bioorg. Med. Chem. Lett. 15, 3247-3251 (2005). (Pubitemid 40799068)
63. Park M, Toporowski JW, Bruice TC. Ribonucleic guanidine demonstrates an unexpected marked preference for complementary DNA rather than RNA. Bioorg. Med. Chem. 14, 1743-1749 (2006). (Pubitemid 43199508)
64. Zhang X, Bruice TC. Complexation of single strand telomere and telomerase RNA template polyanions by deoxyribonucleic guanidine (DNG) polycations: Plausible anticancer agents. Bioorg. Med. Chem. Lett. 18, 665-669 (2008).
65. Park M, Bruice TC. Development of potential anticancer agents that target the telomere sequence. Bioorg. Med. Chem. Lett. 20, 3982-3986 (2010).
66. Park M, Canzio D, Bruice TC. Incorporation of positively charged ribonucleic guanidine linkages into oligodeoxyribonucleotides: Development of potent antisense agents. Bioorg. Med. Chem. Lett. 18, 2377-2384 (2008). (Pubitemid 351442897)
67. Browne KA, Dempcy RO, Bruice TC. Binding studies of cationic thymidyl deoxyribonucleic guanidine to RNA homopolynucleotides. Proc. Natl Acad. Sci. USA 92, 7051-7055 (1995).
68. Dempcy RO, Browne KA, Bruice TC. Synthesis of a thymidyl pentamer of deoxyribonucleic guanidine and binding studies with DNA homopolynucleotides. Proc. Natl Acad. Sci. USA 92, 6097-6101 (1995).
69. Dempcy RO, Browne KA, Bruice TC. Synthesis of a thymidyl pentamer of deoxyribonucleic guanidine and binding studies with DNA homopolynucleotides. Proc. Natl Acad. Sci. USA 92, 6097-6101 (1995).
70. Luo J, Bruice TC. Nanosecond molecular dynamics study of a polycation ribonucleic guanidine (RNG) duplexed with a complementary DNA oligomer strand. J. Am. Chem. Soc. 119, 6693-6701 (1997). (Pubitemid 27343491)
71. Linkletter BA, Szabo IE, Bruice TC. Solid-phase synthesis of oligopurine deoxynucleic guanidine (DNG) and analysis of binding with DNA oligomers. Nucleic Acids Res. 29, 2370-2376 (2001). (Pubitemid 32514939)
72. Kawasaki AM, Casper MD, Freier SM et al. Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36, 831-841 (1993). (Pubitemid 23118776)
73. Noronha AM, Wilds CJ, Lok CN et al. Synthesis and biophysical properties of arabinonucleic acids (ANA): Circular dichroic spectra, melting temperatures, and ribonuclease H susceptibility of ANA. RNA hybrid duplexes. Biochemistry 39, 7050-7062 (2000). (Pubitemid 30413093)
74. Berger I, Tereshko V, Ikeda H, Marquez VE, Egli M. Crystal structures of B-DNA with incorporated 2'-deoxy-2'-fluoro-arabinofuranosyl thymines: Implications of conformational preorganization for duplex stability. Nucleic Acids Res. 26, 2473-2480 (1998). (Pubitemid 28297351)
75. Wilds CJ, Damha MJ. 2'-deoxy-2'-fluoro-bd- arabinonucleosides and oligonucleotides (2'F-ANA): Synthesis and physicochemical studies. Nucleic Acids Res. 28, 3625-3635 (2000).
76. Lesnik EA, Guinosso CJ, Kawasaki AM et al. Oligodeoxynucleotides containing 2'-O-modified adenosine: Synthesis and effects on stability of DNA:RNA duplexes. Biochemistry 32, 7832-7838 (1993). (Pubitemid 23240831)
77. Teplova M. Minasov G, Tereshko V et al. Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6, 535-539 (1999). Structure of 2'-O-methoxyethyl oligonucleotide, one of the most advanced antisense drugs. (Pubitemid 29252831)
78. Prakash TP, Manoharan M, Kawasaki AN et al. 2'-O-{2-N,N-(dialkyl)aminooxy ethyl} modified antisense oligonucleotides. Org. Lett. 2, 3995-3998 (2000).
79. Prakash TP, Kawasaki AM, Fraser AS, Vasquez G, Manoharan M. Synthesis of 2'-O- 2- (N,N-dimethylamino)oxy ethyl modified nucleosides and oligonucleotides. J. Org. Chem. 67, 357-369 (2002). (Pubitemid 34101238)
80. Prakash TP, Johnston JF, Graham MJ, Condon TP, Manoharan M. 2'-O-2-(N,Ndimethylamino) oxy ethyl-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Nucleic Acids Res. 32, 828-833 (2004). (Pubitemid 38263076)
81. Prakash TP, Kawasaki AM, Lesnik EA, Owens SR, Manoharan M. 2'-O-2-(amino)- 2-oxoethyl oligonucleotides. Org. Lett. 5, 403-406 (2003).
82. Pattanayek R, Sethaphong L, Pan CL et al. Structural rationalization of a large difference in RNA affinity despite a small difference in chemistry between two 2'-O-modified nucleic acid analogues. J. Am. Chem. Soc. 126, 15006-15007 (2004). (Pubitemid 39557243)
83. Prakash TP, Kawasaki AM, Wancewicz EV et al. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl- modified antisense oligonucleotides. J. Med. Chem. 51, 2766-2776 (2008). (Pubitemid 351620798)
84. Imanishi T, Obika S. BNAs: Novel nucleic acid analogs with a bridged sugar moiety. Chem. Commun. 1653-1659 (2002). (Pubitemid 34920576)
85. Obika S, Nanbu D, Hari Y et al. Synthesis of 2'-O,4'-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3'-endo sugar puckering. Tetrahedron Lett. 38, 8735-8738 (1997). (Pubitemid 27504436)
86. Singh SK, Wengel J. Universality of LNA-mediated high-affinity nucleic acid recognition. Chem. Commun. 12, 1247-1248 (1998). (Pubitemid 128675594)
87. Singh SK, Nielsen P, Koshkin AA, Wengel J. LNA (locked nucleic acids): Synthesis and high-affinity nucleic acid recognition. Chem. Commun. 4, 455-456 (1998). (Pubitemid 128675297)
88. Egli M, Minasov G, Teplova M, Kumar R, Wengel J. X-ray crystal structure of a locked nucleic acid (LNA) duplex composed of a palindromic 10-mer DNA strand containing one LNA thymine monomer. Chem. Commun. 7, 651-652 (2001). (Pubitemid 32291317)
89. Kaur H, Babu BR, Maiti S. Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem. Rev. 107, 4672-4697 (2007). (Pubitemid 350225863)
90. Obika S, Rahman SMA, Fujisaka A et al. Bridged nucleic acids: Development, synthesis and properties. Heterocycles 81, 1347-1392 (2010). Comprehensive review of the synthesis of BNA analogs.
91. Wengel J. Synthesis of 3'-C- and 4'-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA). Accounts Chem. Res. 32, 301-310 (1999).
92. Obika S, Hari Y, Sekiguchi M, Imanishi TA. A 2',4'-bridged nucleic acid containing 2-pyridone as a nucleobase: Efficient recognition of a CG interruption by triplex formation with a pyrimidine motif. Angew. Chem. Int. Edit. 40, 2079-2081 (2001). (Pubitemid 33644321)
93. Obika S, Hari Y, Sekiguchi M, Imanishi T. Stable oligonucleotide-directed triplex formation at target sites with CG interruptions: Strong sequence-specific recognition by 2',4'-bridged nucleic-acidcontaining 2-pyridones under physiological conditions. Chem-Eur J. 8, 4796-4802 (2002). (Pubitemid 35265140)
94. Hari Y, Obika S, Sekiguchi M, Imanishi T. Selective recognition of CG interruption by 2',4'-BNA having 1-isoquinolone as a nucleobase in a pyrimidine motif triplex formation. Tetrahedron 59, 5123-5128 (2003). (Pubitemid 36734904)
95. Obika S, Rahman SMA, Song B et al. Synthesis and properties of 3'-amino-2',4'- BNA, a bridged nucleic acid with a N3'→P5' phosphoramidate linkage. Bioorgan. Med. Chem. 16, 9230-9237 (2008).
96. Obika S, Onoda M, Morita K et al. 3'-amino- 2',4'-BNA: Novel bridged nucleic acids having an N3'→P5' phosphoramidate linkage. Chem. Commun. 19, 1992-1993 (2001). (Pubitemid 32964551)
97. Rahman SMA, Seki S, Obika S et al. Highly stable pyrimidine-motif triplex formation at physiological pH values by a bridged nucleic acid analogue. Angew. Chem. Int. Edit. 46, 4306-4309 (2007). (Pubitemid 47040827)
98. Miyashita K, Rahman SMA, Seki S, Obika S, Imanishi T. N-methyl substituted 2',4'-BNANC: A highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization. Chem. Commun. 36, 3765-3767 (2007). (Pubitemid 47404177)
99. Rahman SMA, Seki S, Obika S et al. Design, synthesis, and properties of 2',4'-BNANC: A bridged nucleic acid analogue. J. Am. Chem. Soc. 130, 4886-4896 (2008). (Pubitemid 351500122)
100. Hari Y, Obika S, Onishi R et al. Synthesis and properties of 2'-O,4'-Cmethyleneoxymethylene bridged nucleic acid. Bioorgan. Med. Chem. 14, 1029-1038 (2006). (Pubitemid 43059794)
101. Singh SK, Kumar R, Wengel J. Synthesis of novel bicyclo[2.2.1] ribonucleosides: 2'-aminoand 2'-thio-LNA monomeric nucleosides. J. Org. Chem. 63, 6078-6079 (1998).
102. Sorensen MD, Petersen M, Wengel J. Functionalized LNA (locked nucleic acid): High-affinity hybridization of oligonucleotides containing N-acylated and N-alkylated 2'-amino-LNA monomers. Chem. Commun. 2130-2131 (2003). (Pubitemid 37076080)
103. Lebreton J, Escudier JM, Arzel L, Len C. Synthesis of bicyclonucleosides having a C-C bridge. Chem. Rev. 110, 3371-3418 (2010).
104. Morita K, Hasegawa C, Kaneko M et al. 2'-O,4'-C-ethylene-bridged nucleic acids (ENA): Highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett. 12, 73-76 (2002). (Pubitemid 34008572)
105. Morita K, Takagi M, Hasegawa C et al. Synthesis and properties of 2'-O,4'-Cethylene- bridged nucleic acids (ENA) as effective antisense oligonucleotides. Bioorgan. Med. Chem. 11, 2211-2226 (2003). (Pubitemid 36457848)
106. Varghese OP, Barman J, Pathmasiri W et al. Conformationally constrained 2'-N,4'-Cethylene- bridged thymidine (aza-ENA-T): Synthesis, structure, physical, and biochemical studies of aza-ENA-T-modified oligonucleotides. J. Am. Chem. Soc. 128, 15173-15187 (2006). (Pubitemid 44853529)
107. Srivastava P, Barman J, Pathmasiri W et al. Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: Synthesis, structure, and biochemical studies. J. Am. Chem. Soc. 129, 8362-8379 (2007). (Pubitemid 47035147)
108. Kumar S, Hansen MH, Albaek N et al. Synthesis of functionalized carbocyclic locked nucleic acid analogues by ring-closing diene and enyne metathesis and their influence on nucleic acid stability and structure. J. Org. Chem. 74, 6756-6769 (2009).
109. Seth PP, Vasquez G, Allerson CA et al. Synthesis and biophysical evaluation of 2',4'-constrained 2'-O-methoxyethyl and 2',4'-constrained 2'-O-ethyl nucleic acid analogues. J. Org. Chem. 75, 1569-1581 (2010).
110. Seth PP, Siwkowski A, Allerson CR et al. Short antisense oligonucleotides with novel 2',4'-conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13 (2009).
111. Mathe C, Perigaud C. Recent approaches in the synthesis of conformationally restricted nucleoside analogues. Eur. J. Org. Chem. 1489-1505 (2008).
112. Crnugelj M, Plavec J. NMR conformational study reveals that S-C-N anomeric effect in thionucleosides is weaker than O-C-N anomeric effect in natural nucleosides. Croat. Chem. Acta 74, 381-398 (2001). (Pubitemid 33614370)
113. Jones GD, Lesnik EA, Owens SR, Risen LM, Walker RT. Investigation of some properties of oligodeoxynucleotides containing 4'-thio-2'-deoxynucleotides: Duplex hybridization and nuclease sensitivity. Nucleic Acids Res. 24, 4117-4122 (1996). (Pubitemid 26377323)
114. Jones GD, Altmann KH, Husken D, Walker RT. Duplex- and triplex-forming properties of 4'-thio-modified oligodeoxynucleotide. Bioorg. Med. Chem. Lett. 7, 1275-1278 (1997). (Pubitemid 27223385)
115. Inoue N, Minakawa N, Matsuda A. Synthesis and properties of 4'-thioDNA: Unexpected RNA-like behavior of 4'-thioDNA. Nucleic Acids Res. 34, 3476-3483 (2006).
116. Matsugami A, Ohyama T, Inada M et al. Unexpected A-form formation of 4'-thioDNA in solution, revealed by NMR, and the implications as to the mechanism of nuclease resistance. Nucleic Acids Res. 36, 1805-1812 (2008). (Pubitemid 351494227)
117. Dyson MR, Coe PL, Walker RT. The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogs. J. Med. Chem. 34, 2782-2786 (1991).
118. Hancox EL, Connolly BA, Walker RT. Synthesis and properties of oligodeoxynucleotides containing the analog 2'-deoxy-4'-thiothymidine. Nucleic Acids Res. 21, 3485-3491 (1993). (Pubitemid 23241483)
119. Inoue N, Kaga D, Minakawa N, Matsuda A. Practical synthesis of 2'-deoxy-4'- thioribonucleosides: Substrates for the synthesis of 4'-thioDNA. J. Org. Chem. 70, 8597-8600 (2005). (Pubitemid 41457030)
120. Takahashi M, Minakawa N, Matsuda A. Synthesis and characterization of 2'-modified- 4'-thioRNA: A comprehensive comparison of nuclease stability. Nucleic Acids Res. 37, 1353-1362 (2009).
121. Eschenmoser A. Chemical etiology of nucleic acid structure. Science 284, 2118-2124 (1999).
122. Hendrix C, Rosemeyer H, Verheggen I et al. 1',5'-anhydrohexitol oligonucleotides: Synthesis, base pairing and recognition by regular oligodeoxyribonucleotides and oligoribonucleotides. Chem-Eur J. 3, 110-120 (1997). (Pubitemid 27185114)
123. Herdewijn P. Nucleic acids with a sixmembered 'carbohydrate' mimic in the backbone. Chem. Biodivers. 7, 1-59 (2010). Comprehensive review for six-membered carbohydrate mimics.
124. Bohringer, M. Roth HJ, Hunziker J et al. Why pentose and not hexose nucleic-acids. 2. preparation of oligonucleotides containing 2',3'-dideoxy-b-d-glucopyranosyl buildingblocks. Helv. Chim. Acta 75, 1416-1477 (1992).
125. Froeyen M, Lescrinier E, Kerremans L et al. a-homo-DNA and RNA form a parallel oriented non-A, non-B-type double helical structure. Chem-Eur J. 7, 5183-5194 (2001). (Pubitemid 34555646)
126. Maurinsh Y, Rosemeyer H, Esnouf R et al. Synthesis and pairing properties of oligonucleotides containing 3-hydroxy-4- hydroxymethyl-1-cyclohexanyl nucleosides. Chem-Eur J. 5, 2139-2150 (1999). (Pubitemid 129502703)
127. Allart B, Khan K, Rosemeyer H et al. d-altritol nucleic acids (ANA): Hybridisation properties, stability, and initial structural analysis. Chem-Eur J. 5, 2424-2431 (1999). (Pubitemid 129502680)
128. Wang J, Verbeure B, Luyten I et al. Cyclohexene nucleic acids (CeNA): Serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA. J. Am. Chem. Soc. 122, 8595-8602 (2000).
129. Stirchak EP, Summerton JE, Weller DD. Uncharged stereoregular nucleic-acid analogs. 2. morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res. 17, 6129-6141 (1989). (Pubitemid 19198593)
130. Summerton J, Weller D. Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic A 7, 187-195 (1997). (Pubitemid 27323077)
131. Brown SC, Thomson SA, Veal JM, Davis DG. NMR Solution structure of a peptide nucleic-acid complexed with RNA. Science 265, 777-780 (1994). NMR proved that peptide nucleic acid oligomer-RNA duplex forms antiparallel, right-handed A-like structure. (Pubitemid 24266136)
132. Betts L, Josey JA, Veal JM, Jordan SR. A nucleic-acid triple-helix formed by a peptide nucleic-acid DNA complex. Science 270, 1838-1841 (1995). (Pubitemid 26007234)
133. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-1500 (1991). (Pubitemid 21917487)
134. Nielsen PE. PNA technology. Mol. Biotechnol. 26, 233-248 (2004). (Pubitemid 41490464)
135. Larsen HJ, Bentin T, Nielsen PE. Antisense properties of peptide nucleic acid. BBA-Gene Struct. Expr. 1489, 159-166 (1999).
136. Kumar VA, Ganesh KN. Conformationally constrained PNA analogues: Structural evolution toward DNA/RNA binding selectivity. Accounts Chem. Res. 38, 404-412 (2005). Broad synthesis of peptide nucleic acid oligomer analogs and evaluation of duplex stability. (Pubitemid 40816652)
137. Nielsen PE. Peptide nucleic acid. a molecule with two identities. Accounts Chem. Res. 32, 624-630 (1999).
138. Koziolkiewicz M, Krakowiak A, Kwinkowski M, Boczkowska M, Stec WJ. Stereodifferentiation - the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res. 23, 5000-5005 (1995). (Pubitemid 26012481)
139. Furrer P, Billeci TM, Donati A et al. Structural effect of complete [Rp]- phosphorothioate and phosphorodithioate substitutions in the DNA strand of a model antisense inhibitor-target RNA complex. J. Mol. Biol. 285, 1609-1622 (1999). (Pubitemid 29060459)
140. Rozners E, Katkevica D, Stromberg R. Oligoribonucleotide analogues containing a mixed backbone of phosphodiester and formacetal internucleoside linkages, together with vicinal 2'-O-methyl groups. Chembiochem 8, 537-545 (2007). (Pubitemid 47189287)
141. Lin KY, Pudlo JS, Jones RJ et al. Oligodeoxynucleotides containing 5-(1-propynyl)-2'-deoxyuridine formacetal and thioformacetal dimer synthons. Bioorg. Med. Chem. Lett. 4, 1061-1064 (1994). (Pubitemid 24121118)
142. Rice JS, Gao XL. Conformation of formacetal and 3'-thioformacetal nucleotide linkers and stability of their antisense RNA DNA hybrid duplexes. Biochemistry 36, 399-411 (1997). (Pubitemid 27043476)
143. Albaek N, Petersen M, Nielsen P. Analogues of a locked nucleic acid with three-carbon 2',4'-linkages: Synthesis by ring-closing metathesis and influence on nucleic acid duplex stability and structure. J. Org. Chem. 71, 7731-7740 (2006). (Pubitemid 44470314)
144. Karkare S, Bhatnagar D. Promising nucleic acid analogs and mimics: Characteristic features and applications of PNA, LNA, and morpholino. Appl. Microbiol. Biotechnol. 71, 575-586 (2006). (Pubitemid 44114786)
145. Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal-fluid. J. Biochem. Bioph. Meth. 20, 259-267 (1990). (Pubitemid 20111713)
146. Potter BVL, Romaniuk PJ, Eckstein F. Stereochemical course of DNA hydrolysis by nuclease S1. J. Biol. Chem. 258, 1758-1760 (1983).
147. Potter BVL, Connolly BA, Eckstein F. Synthesis and configurational analysis of a dinucleoside phosphate isotopically chiral at phosphorus - stereochemical course of penicillium-citrum nuclease P1 reaction. Biochemistry 22, 1369-1377 (1983). (Pubitemid 13084558)
148. Ghosh MK, Ghosh K, Dahl O, Cohen JS. Evaluation of some properties of a phosphorodithioate oligodeoxyribonucleotide for antisense application. Nucleic Acids Research 21, 5761-5766 (1993). (Pubitemid 24003107)
149. Gryaznov S, Skorskil T, Cucco C et al. Oligonucleotide N3'→P5' phosphoramidates as antisense agents. Nucleic Acids Res. 24, 1508-1514 (1996).
150. Barawkar DA, Bruice TC. Synthesis, biophysical properties, and nuclease resistance properties of mixed backbone oligodeoxynucleotides containing cationic internucleoside guanidinium linkages: Deoxynucleic guanidine/DNA chimeras. Proc. Natl Acad. Sci. USA 95, 11047-11052 (1998).
151. Cummins LL, Owens SR, Risen LM et al. Characterization of fully 2'-modified oligoribonucleotide heteroduplex and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res. 23, 2019-2024 (1995).
152. Prakash TP, Bhat B. 2'-modified oligonucleotides for antisense therapeutics. Curr. Top Med. Chem. 7, 641-649 (2007). (Pubitemid 46681847)
153. Damha MJ, Wilds CJ, Noronha A et al. Hybrids of RNA and arabinonucleic acids (ANA and 2'F-ANA) are substrates of ribonuclease H. J. Am. Chem. Soc. 120, 13545-13545 (1998).
154. Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911-1918 (2002). (Pubitemid 34537585)
155. Frieden M, Christensen SM, Mikkelsen ND et al. Expanding the design horizon of antisense oligonucleotides with a-L-LNA. Nucleic Acids Res. 31, 6365-6372 (2003). (Pubitemid 37442364)
156. Hendrix C, Rosemeyer H, DeBouvere B et al. 1',5'-anhydrohexitol oligonucleotides: Hybridisation and strand displacement with oligoribonucleotides, interaction with RNase H and HIV reverse transcriptase. Chem-Eur J. 3, 1513-1520 (1997). (Pubitemid 27383717)
157. Hudziak RM, Barofsky E, Barofsky DF et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267-272 (1996). (Pubitemid 27045903)
158. Demidov VV, Potaman VN, Frankkamenetskii MD et al. Stability of peptide nucleic-acids in human serum and cellular-extracts. Biochem. Pharmacol. 48, 1310-1313 (1994). (Pubitemid 24298385)
159. Lendvai G, Velikyan I, Bergstrom M et al. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. Eur. J. Pharm. Sci. 26, 26-38 (2005). (Pubitemid 41097258)
160. Reyderman L, Stavchansky S. Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats. Pharm. Res. 15, 904-910 (1998). (Pubitemid 28307833)
161. Tavitian B, Terrazzino S, Kuhnast B et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat. Med. 4, 467-471 (1998).
162. Geary RS, Watanabe TA, Truong L et al. Absolute bioavailability of 2'-O-(2- methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296, 898-904 (2001). (Pubitemid 32187363)
163. Yu RZ, Geary RS, Monteith DK et al. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 93, 48-59 (2004). (Pubitemid 38081813)
164. Lendvai G, Velikyan I, Estrada S et al. Biodistribution of 68Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat chromogranin-A. Oligonucleotides 18, 33-49 (2008).
165. Fluiter K, ten Asbroek AL, de Wissel MB et al. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31, 953-962 (2003). (Pubitemid 36240433)
166. Marshall WS, Beaton G, Stein CA, Matsukura M, Caruthers MH. Inhibition of human-immunodeficiency-virus activity by phosphorodithioate oligodeoxycytidine. Proc. Natl Acad. Sci. USA 89, 6265-6269 (1992).
167. Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16, 169-180 (2006).
168. Brown DA, Kang SH, Gryaznov SM et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805 (1994). (Pubitemid 24332875)
169. Crooke ST. Antisense Research and Applications. CRC Press (1993). Comprehensive review of pioneering antisense molecules such as phosphorothioate and other non-natural oligonucleotides.
170. van Deutekom JC, Janson AA, Ginjaar IB et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New Engl. J. Med. 357, 2677-2686 (2007).
171. Lu QL, Rabinowitz A, Chen YC et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci. USA 102, 198-203 (2005). (Pubitemid 40094452)
172. Heemskerk HA, de Winter CL, de Kimpe SJ et al. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257-266 (2009). Direct comparison of potency of two different antisense for Duchenne muscular dystrophy treatment.
173. Heemskerk H, de Winter C, van Kuik P et al. Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 18, 1210-1217 (2010).
174. Yu RZ, Kim TW, Hong A et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35, 460-468 (2007). (Pubitemid 46333910)
175. Geary RS, Watanabe TA, Truong L et al. Pharmacokinetic properties of 2'-O-(2- methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897 (2001). (Pubitemid 32187362)
176. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884 (2005).
177. Graham MJ, Lemonidis KM, Whipple CP et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48, 763-767 (2007). (Pubitemid 46557881)
178. Yu RZ, Lemonidis KM, Graham MJ et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77, 910-919 (2009).
179. Merki E, Graham MJ, Mullick AE et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118, 743-753 (2008).
180. Akdim F, Visser ME, Tribble DL et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol. 105, 1413-1419 (2010).
181. Akdim F, Stroes ES, Sijbrands EJ et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55, 1611-1618 (2010).
182. Visser ME, Kastelein JJ, Stroes ES. Apolipoprotein B synthesis inhibition: Results from clinical trials. Curr. Opin. Lipidol. 21, 319-323 (2010).
183. Straarup EM, Fisker N, Hedtjarn M et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38(20), 7100-7111 (2010).
184. Elmen J, Lindow M, Schutz S et al. LNAmediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008). (Pubitemid 351550859)
185. Gupta N, Fisker N, Asselin MC et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 5, E10682 (2010).
186. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
187. Elmen J, Lindow M, Silahtaroglu A et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36(4), 1153-1162 (2008). (Pubitemid 351330933)
188. Straarup EM, Fisker N, Hedtjarn M et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38, 7100-7111 (2010). Novel method for the improvement of potency of antisense.
189. Swayze EE, Siwkowski AM, Wancewicz EV et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700 (2007). (Pubitemid 46232083)
190. Gait MJ. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell. Mol. Life Sci. 60, 844-853 (2003). (Pubitemid 36735115)
191. Hamzavi R, Dolle F, Tavitian B, Dahl O, Nielsen PE. Modulation of the pharmacokinetic properties of PNA: Preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers. Bioconjugate Chem. 14, 941-954 (2003). (Pubitemid 37152953)
192. Ivanova GD, Arzumanov A, Abes R et al. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res. 36, 6418-6428 (2008).
193. Yin H, Betts C, Saleh AF et al. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol. Ther. 18, 819-827 (2010).
194. Fabani MM, Abreu-Goodger C, Williams D et al. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res. 38, 4466-4475 (2010).
195. Amantana A, Iversen PL. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 5, 550-555 (2005). (Pubitemid 41258575)
196. Fabani MM, Gait MJ. miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 14, 336-346 (2008). (Pubitemid 351171593)
197. Alotte C, Martin A, Caldarelli SA et al. Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro. Antiviral Res. 80, 280-287 (2008).
198. Kipshidze N, Iversen P, Overlie P et al. First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. Cardiovasc. Revasc. Med. 8, 230-235 (2007). (Pubitemid 350161452)
199. Yokota T, Lu QL, Partridge T et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol. 65, 667-676 (2009).
200. Fletcher S, Honeyman K, Fall AM et al. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med. 8, 207-216 (2006). (Pubitemid 43250701)
201. Aartsma-Rus A, Kaman WE, Bremmer- Bout M et al. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther. 11, 1391-1398 (2004). (Pubitemid 39263892)
202. Goyenvalle A, Babbs A, Powell D et al. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer- mediated exonskipping. Mol. Ther. 18, 198-205 (2010).
203. Rimessi P, Sabatelli P, Fabris M et al. Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. Mol. Ther. 17, 820-827 (2009).
204. Jearawiriyapaisarn N, Moulton HM, Buckley B et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 16, 1624-1629 (2008).
205. Alter J, Lou F, Rabinowitz A et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175-177 (2006). (Pubitemid 43214742)
206. Lu QL, Mann CJ, Lou F et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9, 1009-1014 (2003). (Pubitemid 37021780)
207. Moulton JD, Jiang S. Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 14, 1304-1323 (2009).
208. O'Brien S, Moore JO, Boyd TE et al. Randomized Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 25, 1114-1120 (2007). (Pubitemid 46596764)
209. O'Brien S, Moore JO, Boyd TE et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol. 27, 5208-5212 (2009).
210. Paz-Ares L, Douillard JY, Koralewski P et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-a antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 24, 1428-1434 (2006). (Pubitemid 46622009)
211. Goel S, Desai K, Macapinlac M et al. A Phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1a in patients with advanced solid cancers. Invest. New Drugs 24, 125-134 (2006). (Pubitemid 43723904)
212. Schimmer AD, Estey EH, Borthakur G et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J. Clin. Oncol. 27, 4741-4746 (2009).
213. Takeshima Y, Yagi M, Wada H. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr. Res. 59, 690-694 (2010). (Pubitemid 43740012)
214. Aartsma-Rus A, van Ommen GJ. Antisensemediated exon skipping: A versatile tool with therapeutic and research applications. RNA-A Publication of the RNA Society 13, 1609-1624 (2007). (Pubitemid 47481669)
215. Guglieri M, Bushby K. Molecular treatments in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 10, 331-337 (2010).